Literature DB >> 16760229

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.

Xingrong Liu1, Bill J Smith, Cuiping Chen, Ernesto Callegari, Stacey L Becker, Xi Chen, Julie Cianfrogna, Angela C Doran, Shawn D Doran, John P Gibbs, Natilie Hosea, Jianhua Liu, Frederick R Nelson, Mark A Szewc, Jeffrey Van Deusen.   

Abstract

This study was designed to evaluate the use of cerebrospinal fluid (CSF) drug concentration and plasma unbound concentration (C(u,plasma)) to predict brain unbound concentration (C(u,brain)). The concentration-time profiles in CSF, plasma, and brain of seven model compounds were determined after subcutaneous administration in rats. The C(u,brain) was estimated from the product of total brain concentrations and unbound fractions, which were determined using brain tissue slice and brain homogenate methods. For theobromine, theophylline, caffeine, fluoxetine, and propranolol, which represent rapid brain penetration compounds with a simple diffusion mechanism, the ratios of the area under the curve of C(u,brain)/C(CSF) and C(u,brain)/C(u,plasma) were 0.27 to 1.5 and 0.29 to 2.1, respectively, using the brain slice method, and were 0.27 to 2.9 and 0.36 to 3.9, respectively, using the brain homogenate method. A P-glycoprotein substrate, CP-141938 (methoxy-3-[(2-phenyl-piperadinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide), had C(u,brain)/C(CSF) and C(u,brain)/C(u,plasma) ratios of 0.57 and 0.066, using the brain slice method, and 1.1 and 0.13, using the brain homogenate method, respectively. The slow brain-penetrating compound, N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl-]sarcosine, had C(u,brain)/C(CSF) and C(u,brain)/C(u,plasma) ratios of 0.94 and 0.12 using the brain slice method and 0.15 and 0.018 using the brain homogenate method, respectively. Therefore, for quick brain penetration with simple diffusion mechanism compounds, C(CSF) and C(u,plasma) represent C(u,brain) equally well; for efflux substrates or slow brain penetration compounds, C(CSF) appears to be equivalent to or more accurate than C(u,plasma) to represent C(u,brain). Thus, we hypothesize that C(CSF) is equivalent to or better than C(u,plasma) to predict C(u,brain). This hypothesis is supported by the literature data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760229     DOI: 10.1124/dmd.105.008201

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Cerebrospinal fluid cortisol and progesterone profiles and outcomes prognostication after severe traumatic brain injury.

Authors:  Martina Santarsieri; Christian Niyonkuru; Emily H McCullough; Julie A Dobos; C Edward Dixon; Sarah L Berga; Amy K Wagner
Journal:  J Neurotrauma       Date:  2014-02-06       Impact factor: 5.269

Review 3.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

4.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

Review 5.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

6.  Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain.

Authors:  Mingyan Zhou; Karen Engel; Joanne Wang
Journal:  Biochem Pharmacol       Date:  2006-09-14       Impact factor: 5.858

7.  Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Samuel A Roiko; Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

9.  A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.

Authors:  An-Chi Tien; Jing Li; Xun Bao; Alanna Derogatis; Seongho Kim; Shwetal Mehta; Nader Sanai
Journal:  Clin Cancer Res       Date:  2019-07-08       Impact factor: 12.531

10.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.